CW2IP2: Imaging and Diagnostic Assessments
Tauopathies
About this trial
This is an interventional diagnostic trial for Tauopathies focused on measuring Amyloid PET, Movement disorders
Eligibility Criteria
Inclusion Criteria: Participants: Patients in all cohorts will range from 40 to 85 yrs and will be both male and female. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Participants who are deemed unable to provide informed consent must have a designated Legally Authorized Representative(LAR) present for consent and a Study Partner to accompany them to study visits. The LAR and the Study Partner may be the same person. Clinical diagnoses for each cohort will be determined by consensus committee for diagnostic agreement (PD, MSA, PSP, FTD or Healthy control) Exclusion Criteria: Females who are pregnant or breast feeding at the time of screening will be excluded Forms of parkinsonism other than PD, PSP and MSA as defined above Major psychiatric disorder (e.g. schizophrenia or bipolar disorder) History of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported Contraindications or Inability to tolerate imaging, arterial line or IV placement or blood draw procedures in the opinion of an investigator or treating physician Implanted medical device or other contraindication to MRI Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician or investigator to be a condition that could compromise participant safety or successful participation in the study Refusal to consent to brain donation (except for HC cohort). All non-HC participants must agree to postmortem brain donation..
Sites / Locations
- University of PennsylvaniaRecruiting
Arms of the Study
Arm 1
Other
Diagnostic Assessments
Subjects may receive an Amyloid PET scan, a brain MRI and neurological exam with diagnostic assessments.